[Epidermolysis bullosa acquisita and hepatitis C]. 1998

S Thiery, and L Misery, and P Chossegros, and J Kanitakis, and R Ghohestani, and J Y Forestier, and C Trepo, and M Faure, and A Claudy
Clinique Dermatologique, Hôpital Edouard Herriot, Lyon.

BACKGROUND Epidermolysis bullosa acquisita is a bullous dermatosis. Its etiology remains unknown and the efficacy of its treatment is low. METHODS We report the first association between epidermolysis bullosa acquisita, chronic hepatitis C and cryoglobulinemia, healing with interferon alpha and ribavirine. CONCLUSIONS We suggest a role for hepatitis C virus in the pathogenesis of epidermolysis bullosa acquisita. We suppose a synthesis of autoimmune antibodies in a dysimmune environment. Interferon alpha and ribavirine might be a new therapeutic avenue but further studies are necessary to confirm it.

UI MeSH Term Description Entries
D005260 Female Females
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012254 Ribavirin A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. Ribovirin,Tribavirin,ICN-1229,Rebetol,Ribamide,Ribamidil,Ribamidyl,Ribasphere,Vilona,Viramide,Virazide,Virazole,ICN 1229,ICN1229
D016107 Epidermolysis Bullosa Acquisita Form of epidermolysis bullosa characterized by trauma-induced, subepidermal blistering with no family history of the disease. Direct immunofluorescence shows IMMUNOGLOBULIN G deposited at the dermo-epidermal junction. Epidermolysis Bullosa, Acquired,Acquired Form of Epidermolysis Bullosa,Acquired Epidermolysis Bullosa
D016898 Interferon-alpha One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. Interferon Alfa,Interferon, Leukocyte,Interferon, Lymphoblast,alpha-Interferon,IFN-alpha D,IFN-alpha5,Interferon alpha-1,Interferon alpha-17,Interferon alpha-4,Interferon alpha-5,Interferon alpha-7,Interferon alpha-88,Interferon alpha-J,Interferon alpha-T,Interferon alpha4,Interferon alpha5,Interferon, Lymphoblastoid,Interferon, alpha,LeIF I,LeIF J,Leif D,IFN alpha D,IFN alpha5,Interferon alpha,Interferon alpha 1,Interferon alpha 17,Interferon alpha 4,Interferon alpha 5,Interferon alpha 7,Interferon alpha 88,Interferon alpha J,Interferon alpha T,Leukocyte Interferon,Lymphoblast Interferon,Lymphoblastoid Interferon,alpha Interferon

Related Publications

S Thiery, and L Misery, and P Chossegros, and J Kanitakis, and R Ghohestani, and J Y Forestier, and C Trepo, and M Faure, and A Claudy
May 2006, Journal of the American Academy of Dermatology,
S Thiery, and L Misery, and P Chossegros, and J Kanitakis, and R Ghohestani, and J Y Forestier, and C Trepo, and M Faure, and A Claudy
October 2010, Presse medicale (Paris, France : 1983),
S Thiery, and L Misery, and P Chossegros, and J Kanitakis, and R Ghohestani, and J Y Forestier, and C Trepo, and M Faure, and A Claudy
November 1994, The British journal of dermatology,
S Thiery, and L Misery, and P Chossegros, and J Kanitakis, and R Ghohestani, and J Y Forestier, and C Trepo, and M Faure, and A Claudy
January 1989, Indian journal of dermatology, venereology and leprology,
S Thiery, and L Misery, and P Chossegros, and J Kanitakis, and R Ghohestani, and J Y Forestier, and C Trepo, and M Faure, and A Claudy
August 1988, The American Journal of dermatopathology,
S Thiery, and L Misery, and P Chossegros, and J Kanitakis, and R Ghohestani, and J Y Forestier, and C Trepo, and M Faure, and A Claudy
October 2013, Journal of the European Academy of Dermatology and Venereology : JEADV,
S Thiery, and L Misery, and P Chossegros, and J Kanitakis, and R Ghohestani, and J Y Forestier, and C Trepo, and M Faure, and A Claudy
July 1981, Archives of dermatology,
S Thiery, and L Misery, and P Chossegros, and J Kanitakis, and R Ghohestani, and J Y Forestier, and C Trepo, and M Faure, and A Claudy
January 2006, Indian journal of dermatology, venereology and leprology,
S Thiery, and L Misery, and P Chossegros, and J Kanitakis, and R Ghohestani, and J Y Forestier, and C Trepo, and M Faure, and A Claudy
December 2017, Dermatology online journal,
S Thiery, and L Misery, and P Chossegros, and J Kanitakis, and R Ghohestani, and J Y Forestier, and C Trepo, and M Faure, and A Claudy
September 1988, Seminars in dermatology,
Copied contents to your clipboard!